No profile data available.
Keros Therapeutics, Inc. (KROS) is a healthcare company in the blood disorder treatment drugs industry, based in Lexington, United States, with about 92 full-time employees.
It reported revenue of $244.06 million for fiscal year 2025, up 6775.0% from fiscal year 2024, and net income of $87.01 million. Its market capitalization was $236.93 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States.
Keros Therapeutics reported $244.06 million in revenue for fiscal year 2025, up 6775.0% from $3.55 million in fiscal year 2024.
$236.93 million as of October 9, 2026.
Listed companies of a similar size in the same industry (blood disorder treatment drugs) include Ardelyx, Inc. (ARDX), Geron Corporation (GERN), Rocket Pharmaceuticals, Inc. (RCKT), Coherus Oncology, Inc. (CHRS).